OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 12 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period).
Traditional Chinese Medicine for Geriatrics
Submission Deadline: September 30, 2021 (Open) Submit Now
Koh Iwasaki, MD, PhD
Vice President, Natori Kumanodoh Hospital, Natori, Japan
Research Interests: Traditional Chinese medicine; stroke; healthcare; traditional medicine; clinical trials; geriatric medicine; phytotherapy; herbal medicine
About This Topic
Traditional Chinese Medicine (TCM) addressed gerontology even 2000 years ago. In ancient China, people considered this phenomenon as the deficiency of Qi (気) in the kidney (shen xu, 腎虚). Qi is energy and signaling using energy. The kidney in traditional Chinese medicine (TCM) is very different from the Kidney in Western medicine. TCM kidney is somewhat the base of life. A human inherits the essence of life (jing, 精) from his/her parents and keeps it all his/her life. People die when jing runs out. TCM kidney is the box that keeps jing. When people become old, the jing in the TCM kidney decreases and the function of the whole body deteriorates. This is the reason for aging and geriatric syndrome. These thoughts were well coded in the famous ancient medical text book Huan di nei jing (黄帝内経), written in the second to first century BC. Thus, we invite articles in TCM concerning frailty or geriatric syndrome.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.